Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17878594 | 0.89 | CYP3A4 (0.47) | LPAR3LPAR1LPAR2CYP3A4 | |
| SCHEMBL7055977 | 0.83 | TSHR (0.46) | CYP3A4 | |
| SCHEMBL17878599 | 0.81 | PPARD (0.35) | MEN1KMT2A | |
| SCHEMBL2994532 | 0.77 | MEN1 (0.35) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL17860961 | 0.75 | MEN1 (0.34) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL2990947 | 0.75 | TDP1 (0.38) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL3939885 | 0.74 | LMNA (0.31) | — | |
| SCHEMBL15951719 | 0.73 | POLB (0.39) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL2237874 | 0.73 | NAAA (0.36) | MEN1KMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL2351213 | 0.72 | MGAM (0.43) | CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | MEN1 2965/4885KMT2A 4316/4885LPAR3 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.